Ligand Pharmaceuticals Incorporated (LGND) is a Healthcare · Biotechnology company listed on NASDAQ. Price $284.76 (+0.02%), Market cap $4.16B, P/E ratio 27.09, 52-week low–high $100.19 ~ $241.79.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a
Financial statements, price targets, institutional (13F) holdings and related news for Ligand Pharmaceuticals Incorporated are updated in real time on BlackAll Trade.
Ligand Pharmaceuticals Incorporated trades at $284.76 (+0.02%). Real-time quotes and charts are available on BlackAll Trade.
Ligand Pharmaceuticals Incorporated has a market cap of about $4.16B. Its P/E ratio is 27.09.
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFiv